BRPI0207102A8 - forma cristalina, composição farmacêutica, e, uso de uma forma cristalina. - Google Patents

forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.

Info

Publication number
BRPI0207102A8
BRPI0207102A8 BRPI0207102A BRPI0207102A BRPI0207102A8 BR PI0207102 A8 BRPI0207102 A8 BR PI0207102A8 BR PI0207102 A BRPI0207102 A BR PI0207102A BR PI0207102 A BRPI0207102 A BR PI0207102A BR PI0207102 A8 BRPI0207102 A8 BR PI0207102A8
Authority
BR
Brazil
Prior art keywords
crystalline form
pharmaceutical composition
crystals
preventing
formula
Prior art date
Application number
BRPI0207102A
Other languages
English (en)
Inventor
Numagami Eiji
Ohtsuka Keiichi
Harashima Susumu
Takita Takashi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0207102A8 publication Critical patent/BRPI0207102A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"forma cristalina, composição farmacêutica, uso de uma forma cristalina,, e, método para a prevenção ou o tratamento de doença". cristais de um derivado de nucleosídeo de pirimidina possuindo excelente atividade antitumor. são cristais de composto representado pela fórmula (i).
BRPI0207102A 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina. BRPI0207102A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09
PCT/JP2002/000986 WO2002064609A1 (fr) 2001-02-09 2002-02-06 Cristaux de derive de nucleoside de pyrimidine

Publications (1)

Publication Number Publication Date
BRPI0207102A8 true BRPI0207102A8 (pt) 2018-02-27

Family

ID=18896929

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0207102-9A BR0207102A (pt) 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
BRPI0207102A BRPI0207102A8 (pt) 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0207102-9A BR0207102A (pt) 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença

Country Status (21)

Country Link
EP (1) EP1364959B1 (pt)
JP (2) JP3748536B2 (pt)
KR (1) KR100679904B1 (pt)
CN (1) CN100408591C (pt)
AT (1) ATE361929T1 (pt)
AU (1) AU2002230164B2 (pt)
BR (2) BR0207102A (pt)
CA (1) CA2437994C (pt)
CY (1) CY1106685T1 (pt)
CZ (1) CZ303241B6 (pt)
DE (1) DE60220024T2 (pt)
DK (1) DK1364959T3 (pt)
ES (1) ES2286237T3 (pt)
HU (1) HU229294B1 (pt)
IL (2) IL157216A0 (pt)
MX (1) MXPA03007123A (pt)
NZ (1) NZ527393A (pt)
PT (1) PT1364959E (pt)
RU (1) RU2256666C2 (pt)
WO (1) WO2002064609A1 (pt)
ZA (1) ZA200306121B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101084525B1 (ko) 1999-09-02 2011-11-18 이비덴 가부시키가이샤 프린트배선판 및 그 제조방법
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
CN102088969B (zh) 2008-06-09 2013-06-12 西克拉塞尔有限公司 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2016144660A1 (en) 2015-03-09 2016-09-15 W.R. Grace & Co.-Conn. Crystalline form of nicotinamide riboside
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения

Also Published As

Publication number Publication date
HUP0303159A3 (en) 2007-06-28
PT1364959E (pt) 2007-07-23
CA2437994A1 (en) 2002-08-22
CN100408591C (zh) 2008-08-06
EP1364959B1 (en) 2007-05-09
HUP0303159A2 (hu) 2003-12-29
CY1106685T1 (el) 2012-05-23
KR20030081424A (ko) 2003-10-17
EP1364959A4 (en) 2004-03-24
CZ303241B6 (cs) 2012-06-13
DE60220024T2 (de) 2007-11-22
IL157216A0 (en) 2004-02-19
RU2256666C2 (ru) 2005-07-20
EP1364959A1 (en) 2003-11-26
HU229294B1 (en) 2013-10-28
ZA200306121B (en) 2005-01-26
JP4356998B2 (ja) 2009-11-04
KR100679904B1 (ko) 2007-02-07
AU2002230164B2 (en) 2005-04-07
JP3748536B2 (ja) 2006-02-22
JP2002308895A (ja) 2002-10-23
CZ20032111A3 (cs) 2003-12-17
RU2003124648A (ru) 2005-02-27
DE60220024D1 (en) 2007-06-21
CA2437994C (en) 2011-05-17
BR0207102A (pt) 2004-01-27
IL157216A (en) 2008-03-20
ES2286237T3 (es) 2007-12-01
ATE361929T1 (de) 2007-06-15
NZ527393A (en) 2004-07-30
CN1501939A (zh) 2004-06-02
WO2002064609A1 (fr) 2002-08-22
MXPA03007123A (es) 2003-11-18
JP2006008699A (ja) 2006-01-12
DK1364959T3 (da) 2007-06-04

Similar Documents

Publication Publication Date Title
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20035524D0 (no) 4'-substituerte nukleosider
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0109703A (pt) Derivados de piperazina
BRPI0411365A (pt) derivados de aminopiridina
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
DE60204452D1 (de) Pyrazolo[1,5]pyridinderivate
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20040881L (no) Orale antidiabetes midler.
GEP20064021B (en) Hetero biaryl derivatives as matrix metalloproteinase inhibitors
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
NO984470L (no) Pyrrolopyrrolon-derivater som inhibitorer for neutrofil elastase
ATE238981T1 (de) Antitumorwirkstoffe
BRPI0207102A8 (pt) forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.
SE9804212D0 (sv) Compounds
MXPA04006041A (es) Antivirales de piridoquinoxalina.
TR200001452T2 (tr) Bifenilamidin türevleri.
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
EA200600046A1 (ru) Производные 6-[2-(фосфонометокси)алкокси]пиримидинов (варианты), способ их получения (варианты), фармацевтическая композиция на их основе и способ лечения вирусной инфекции
BR0215067A (pt) Piridoquinoxalinas antivirais